7,8-Dihydro-14-hydroxy- normorphinone Chemical Properties

Melting point:

>265°C (dec.)

Boiling point:

552.1±50.0 °C(Predicted)

Density 

1.54±0.1 g/cm3(Predicted)

Flash point:

22℃

storage temp. 

Controlled Substance, -20°C Freezer

solubility 

DMF: 20 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml; DMSO: 10 mg/ml

form 

A crystalline solid

pka

9.20±0.40(Predicted)

Stability:

Hygroscopic

InChI

InChI=1/C16H17NO4/c18-9-2-1-8-7-11-16(20)4-3-10(19)14-15(16,5-6-17-11)12(8)13(9)21-14/h1-2,11,14,17-18,20H,3-7H2/t11-,14+,15+,16-/s3

InChIKey

HLMSIZPQBSYUNL-RSBMUYHFNA-N

SMILES

O[C@]12CCC(=O)[C@]3([H])OC4=C(C=CC5C[C@@]1([H])NCC[C@@]23C4=5)O |&1:1,6,15,20,r|

Safety Information

Hazard Codes 

T,F

Risk Statements 

10-23/24/25-39/23/24/25-11

Safety Statements 

36/37-45-16-7

RIDADR 

UN1230 - class 3 - PG 2 - Methanol, solution

WGK Germany 

1

DEA Controlled Substances

CSCN: 9668
CSA SCH: Schedule II
NARC: Yes

7,8-Dihydro-14-hydroxy- normorphinone Usage And Synthesis

Description

Noroxymorphone (Item No. 15903) is an analytical reference standard that is structurally categorized as an opioid. It is an active metabolite of oxycodone , noroxycodone (Item Nos. 15902 | 20407), and oxymorphone that can be detected in plasma and urine. Noroxymorphone is also an immediate precursor in the synthesis of several opioids, including naltrexone (Item Nos. 15520 | ISO60192) and naloxone (Item Nos. 15594 | ISO60191). Noroxymorphone is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.

Chemical Properties

Off-White to Light Brown Solid

Uses

A metabolite of Naloxone and Naltrexone

Definition

ChEBI: Noroxymorphone is a member of phenanthrenes.

References

[1] CHAD M THOMPSON. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.[J]. Journal of Pharmacology and Experimental Therapeutics, 2004, 308 2: 547-554. DOI: 10.1124/jpet.103.058602
[2] MERJA KOKKI. Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine[J]. British journal of clinical pharmacology, 2016, 83 4: 791-800. DOI: 10.1111/bcp.13164
[3] TIMO KORJAMO. Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.[J]. ACS Applied Energy Materials, 2012: 87. DOI: 10.3389/fphar.2011.00087
[4] BOJAN LALOVIC. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.[J]. ACS Applied Energy Materials, 2004: 447-454. DOI: 10.1124/dmd.32.4.447
[5] DR. BERNHARD GUTMANN. Batch- and Continuous-Flow Aerobic Oxidation of 14-Hydroxy Opioids to 1,3-Oxazolidines—A Concise Synthesis of Noroxymorphone[J]. Chemistry - A European Journal, 2016, 22 30: 10393-10398. DOI: 10.1002/chem.201601902

7,8-Dihydro-14-hydroxy- normorphinone(33522-95-1)Related Product Information

• Sorafenib related coMpound 8
• Posaconazole DiastereoisoMer interMediate 2
• 16α,17-[(1RS)-Butylidenebis(oxy)]-11β-hydroxy-17-(hydroxyMethyl)-D-hoMoandrosta-1,4-diene-3,17a-dione (Mixture of DiastereoMers)
• N-(2-AMINOETHYL)-2-(1-NAPHTHYL)ACETAMIDE
• Benzoic acid
• 3-(2-Furyl)acrylic acid
• Nalfurafine
• 10α-Hydroxy-nalfurafine
• N-(3-Butenyl) NoroxyMorphone Hydrochloride
• Methisosildenafil impure
• Acotiamide Impurity
• Terazosin EP Impurity O
• Methisosildenafil Impurity
• Methyl 2-(2-hydroxy-4,5-diMethoxybenzaMido)thiazole-4-carboxylate
• Donepezil Impurity
• 3,5-Dimethyl-piperazine-1-carboxylic acid tert-butyl ester
• Sildenafil Chlorosulfonyl
• diethyl 2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-4,5-dicarboxylate